CTBP1 and diabetes mellitus: In conclusion, ErL demonstrated anti-inflammaging influence in diabetes-associated periodontitis in vitro and it is proposed to be mediated through the CTBP1-AS2/miR-155/SIRT1 axis and, therefore, could be a potential therapeutic target in DM patients with periodontitis.